The Technology and Life Sciences teams advised DNA Script on its €142 million Series C financing led by American investors Coatue Management and Catalio Capital Management.
New American investors Fidelity Management and Research, Columbia Threadneedle Investments, Arrowmark Partners, Farallon Capital and Moore Strategic Ventures joined the round. Existing investors Casdin Capital, LSP, Illumina Ventures, Bpifrance Large Venture Fund, Danaher Life Sciences, Agilent Technologies, M Ventures, Kurma Partners and Alexandria Venture Investments also participated in the round.
Founded in 2014, DNA Script is a pioneering French life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids. The company has developed an alternative to traditional DNA synthesis called Enzymatic DNA Synthesis, or EDS, allowing this technology to be accessible to labs with the first benchtop enzymatic synthesis instrument, the SYNTAX System.
The financing will allow DNA Script to accelerate expansion and commercialization of the company’s SYNTAX System and broaden the portfolio of products powered by EDS.
The Goodwin team was led by Anne-Charlotte Rivière, Johann Gandilhon.